Raab & Moskowitz Asset Management Has Increased Its Johnson & Johnson Com (JNJ) Position; Intec Pharma Limited Ord (NTEC) SI Decreased By 72.73%

June 20, 2017 - By Dolores Ford

Raab & Moskowitz Asset Management Llc increased Johnson & Johnson Com (JNJ) stake by 8.04% reported in 2016Q4 SEC filing. Raab & Moskowitz Asset Management Llc acquired 3,476 shares as Johnson & Johnson Com (JNJ)’s stock rose 6.85%. The Raab & Moskowitz Asset Management Llc holds 46,707 shares with $5.38M value, up from 43,231 last quarter. Johnson & Johnson Com now has $361.40 billion valuation. The stock rose 0.28% or $0.37 reaching $134.44 per share. About 2.18 million shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since June 20, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

Intec Pharma Limited Ord (NASDAQ:NTEC) had a decrease of 72.73% in short interest. NTEC’s SI was 900 shares in June as released by FINRA. Its down 72.73% from 3,300 shares previously. With 5,100 avg volume, 0 days are for Intec Pharma Limited Ord (NASDAQ:NTEC)’s short sellers to cover NTEC’s short positions. The SI to Intec Pharma Limited Ord’s float is 0.01%. About 7,264 shares traded. Intec Pharma Ltd (NASDAQ:NTEC) has risen 51.00% since June 20, 2016 and is uptrending. It has outperformed by 34.30% the S&P500.

Investors sentiment increased to 0.94 in 2016 Q4. Its up 0.12, from 0.82 in 2016Q3. It increased, as 63 investors sold JNJ shares while 834 reduced holdings. 114 funds opened positions while 731 raised stakes. 1.72 billion shares or 0.88% more from 1.71 billion shares in 2016Q3 were reported. Princeton Alpha Mngmt LP has 0.59% invested in Johnson & Johnson (NYSE:JNJ) for 25,042 shares. Janney Capital Limited Co owns 370,849 shares. Moreover, Mitsubishi Ufj Trust Banking Corporation has 1.39% invested in Johnson & Johnson (NYSE:JNJ) for 5.77M shares. 1.01 million were accumulated by Cincinnati Insurance. Independent Investors stated it has 5.16% in Johnson & Johnson (NYSE:JNJ). Amica Mutual accumulated 154,191 shares or 1.59% of the stock. Manning Napier owns 2.94 million shares. Atria Invs Lc has 0.62% invested in Johnson & Johnson (NYSE:JNJ). Toronto Dominion Financial Bank reported 0.37% stake. Moreover, Atlantic Gp Limited Liability Company has 1.29% invested in Johnson & Johnson (NYSE:JNJ) for 1.70M shares. 55,932 are held by First Comml Bank & Of Newtown. Amica Retiree Med owns 16,629 shares. Alethea Capital Management Limited Com, a California-based fund reported 17,256 shares. Wilbanks Smith & Thomas Asset Management Ltd Company reported 77,358 shares. Salient Trust Lta, Texas-based fund reported 171,328 shares.

Among 16 analysts covering Johnson & Johnson (NYSE:JNJ), 8 have Buy rating, 1 Sell and 7 Hold. Therefore 50% are positive. Johnson & Johnson had 44 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, July 20. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by Deutsche Bank on Tuesday, September 29. The stock of Johnson & Johnson (NYSE:JNJ) has “Buy” rating given on Wednesday, October 19 by UBS. The firm has “Buy” rating by BMO Capital Markets given on Friday, June 2. The firm has “Outperform” rating given on Wednesday, October 7 by RBC Capital Markets. As per Monday, August 31, the company rating was downgraded by Vetr. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, January 25. Jefferies maintained the stock with “Hold” rating in Thursday, July 14 report. As per Tuesday, September 13, the company rating was maintained by Jefferies. The firm has “Buy” rating by S&P Research given on Wednesday, October 14.

Since February 1, 2017, it had 0 insider purchases, and 5 sales for $14.98 million activity. On Tuesday, February 28 the insider Pruden Gary J sold $1.99M. Stoffels Paulus sold $2.58M worth of stock. Duato Joaquin had sold 50,000 shares worth $6.18M. Kapusta Ronald A also sold $1.78M worth of Johnson & Johnson (NYSE:JNJ) on Tuesday, February 28. On Wednesday, February 1 the insider Ullmann Michael H sold $2.45 million.

Among 3 analysts covering Intec Pharma (NASDAQ:NTEC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intec Pharma had 3 analyst reports since September 11, 2015 according to SRatingsIntel. The stock of Intec Pharma Ltd (NASDAQ:NTEC) has “Buy” rating given on Friday, September 11 by Roth Capital. Maxim Group initiated Intec Pharma Ltd (NASDAQ:NTEC) on Wednesday, September 16 with “Buy” rating. TH Capital initiated Intec Pharma Ltd (NASDAQ:NTEC) on Friday, September 11 with “Buy” rating.

Intec Pharma Ltd is an Israel-based drug development company. The company has market cap of $74.12 million. It is a development stage biopharmaceutical firm that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. It currently has negative earnings. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: